Navigation Links
FDA Approves INTUNIV (guanfacine) for the Treatment of ADHD

Shire announced today that it has received an approvable letter from the US Food and Drug Administration (FDA) for INTUNIV (guanfacine) extended release tablets (previously referred to as SPD503), a nonstimulant selective alpha-2A-receptor agonist, which has been studied in children and adolescents with Attention-Deficit/Hyperactivity Disorder (ADHD). Unlike some other ADHD treatments, INTUNIV, a nonstimulant, is not a controlled substance and does not have a known mechanism for potential abuse or dependence. The information requested by the FDA was not unexpected, and Shire is working with the FDA to provide a full and timely response to the agency's request.

"The FDA's approvable letter for INTUNIV is positive news, and Shire will be working closely with the agency to address its questions," said Matthew Emmens, CEO of Shire. "When approved, INTUNIV will be the first medication indicated to treat ADHD symptoms by selectively targeting alpha-2A-receptors in the prefrontal cortex, an area of the brain that is thought to manage executive functioning tasks. Shire is looking forward to further strengthening our broad portfolio of ADHD medications by adding a nonstimulant treatment option with a novel mechanism of action and demonstrated clinical efficacy, which may be ideal for those patients who have not benefited from currently available ADHD medications." About INTUNIV (guanfacine) Extended Release Tablets Shire is seeking approval of INTUNIV as monotherapy for the treatment of ADHD symptoms throughout the day in children aged 6 to 17 years, with dosage strengths of 1 mg to 4 mg daily. The INTUNIV New Drug Application (NDA) includes data from two placebo-controlled trials in children and adolescents ages 6 to 17 evaluating the compound's safety and efficacy in controlling ADHD symptoms evaluated on a once-weekly basis using the ADHD Rating Scale (ADHD-RS-IV), which included both hyperactive/impulsive and inattentive subscales. ADHD-RS-IV i s a standardized, validated test for assessing symptoms of ADHD in children and for assessing their response to treatment.

This scale, which contains 18 items, is based on the ADHD diagnostic criteria as defined in the APA's Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision(R). In these two clinical trials, treatment related adverse events greater than 10 percent included somnolence, fatigue, upper abdominal pain, sedation and headache.

INTUNIV, a once-daily formulation of guanfacine, provides a controlled, steady delivery of drug throughout the day and evening with a delivery system that minimizes the fluctuations between peak and trough concentrations as seen with immediate-release guanfacine. It has been shown that guanfacine, the active ingredient in INTUNIV, binds selectively to alpha 2A adrenergic cell receptors located in the part of the brain called the prefrontal cortex.

The prefrontal cortex is an area of the brain associated with executive functioning, i.e., working memory, behavioral inhibition, regulation of attention, distractibility, impulsivity, and frustration tolerance. The selective alpha-2A agonist strengthens working memory and prefrontal cortex neuronal firing. This research supports the use of guanfacine for the treatment of ADHD.




'"/>




Related medicine news :

1. FDA Approves Contraceptive Ring
2. FDA Approves New HIV Drug, Viread
3. FDA Approves Birth Control Skin Patch
4. FDA Approves New Arthritis Drug, Bextra
5. FDA Approves Elidel Cream for Eczema
6. FDA Approves New Anti-Clotting Drug
7. FDA Approves New surgery Treatment for Farsightedness
8. FDA Approves Anti-Cancer Cell Drug - Zevalin
9. FDA Approves Remodulin for Pulmonary Hypertension
10. World Health Organisation Takes a Historic Decision and Approves Treaty to Discourage Smoking
11. World Health Organisation Takes a Historic Decision and Approves Treaty to Discourage Smoking
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/7/2016)... ... December 07, 2016 , ... A quote from Dr. ... of comments on social media that offer a rare glimpse into the mind of ... authority and New York Times bestselling author, has described people with ADHD as having ...
(Date:12/7/2016)... , ... December 07, 2016 , ... ... consultation services from offices located in South Lyon, Dewitt, Williamston, East Lansing, Ann ... basketball coach who needs treatment for a brain tumor. , Jason Bauer and ...
(Date:12/7/2016)... ... 07, 2016 , ... A. Kevin Spann Insurance, a New York-based firm offering ... is launching a charity drive to raise funds that will benefit the Marine Corps ... marines and Navy FMF Corpsmen. Working closely with the MCL, the A. Kevin Spann ...
(Date:12/7/2016)... ... December 07, 2016 , ... Delete® - Tattoo Removal and ... The Holiday Party Season. Save Up To 33% Off Botox® and Juvederm® Products Now ... the Phoenix Valley with Delightful Deals on Botox® and Juvederm® just in ...
(Date:12/7/2016)... ... December 07, 2016 , ... Gensuite is ... Awards under the Best New Product Launch category. Gensuite’s entry on their EZ ... , BOC Global Events & Training Group is a professional event and training ...
Breaking Medicine News(10 mins):
(Date:12/6/2016)...  BTL Aesthetics today announced the release of ... ME device was effectively redesigned for more efficient, ... tissue. The result: Significantly better outcomes in abdominal ... ME versus BTL Vanquish. "We are ... patients with the most highly-advanced devices on the ...
(Date:12/6/2016)... Dec. 6, 2016   Sienna Biopharmaceuticals, ... dermatology and aesthetics company, today announced it ... specialty pharmaceutical company focused on developing first-in-class ... including psoriasis, atopic dermatitis and pruritus (itch). ... will make an undisclosed upfront payment in ...
(Date:12/6/2016)...  Arcturus Therapeutics, Inc. ("Arcturus" or the "Company"), ... it entered into collaboration with Takeda Pharmaceutical Company ... of NASH and other gastrointestinal (GI) related disorders, ... UNA Oligomer chemistry. The financial terms were not ... and expertise in GI disorders, we are confident ...
Breaking Medicine Technology: